SCHEMBL1860045

SCHEMBL1860045

Cc1cccnc1-n1c(C)cc(OS(=O)(=O)C(F)(F)F)cc1=O

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 3/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
MYC P01106 1/20 0.34
HSD11B1 P28845 2/20 0.34
PDE4A P27815 3/20 0.34
PDE4C Q08493 3/20 0.34
PDE4D Q08499 3/20 0.34
POLB P06746 1/20 0.34
TRPV1 Q8NER1 2/20 0.33
PTGS2 P35354 1/20 0.33
HRH3 Q9Y5N1 1/20 0.32
IDO1 P14902 1/20 0.32
HTR7 P34969 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31381681 0.76 PTGS1 (0.34) PTGS2IDO1
SCHEMBL29348764 0.73 MAPT (0.38) ALDH1A1HSD11B1POLBPTGS2
SCHEMBL1865239 0.72 NPSR1 (0.48) NPSR1MEN1KMT2AALDH1A1CYP2C9
SCHEMBL3661917 0.72 PTGS2 (0.37) KMT2APDE4APDE4CPDE4DPTGS2
SCHEMBL1861393 0.72 NOX4 (0.43) ALDH1A1
SCHEMBL31381740 0.71 KCNJ5 (0.35)
SCHEMBL8896304 0.70 CYP1A2 (0.43) KMT2ACYP2C9CYP2C19HSD11B1
SCHEMBL21260401 0.70 PDE4A (0.39) PDE4APDE4CPDE4DTRPV1PTGS2
SCHEMBL3664837 0.69 NOX4 (0.44) ALDH1A1
SCHEMBL1366697 0.66 TRPV1 (0.43) HSD11B1TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426426-B2 Gyrase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-23 US disclosed
US-20110104207-A1 GYRASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-05-05 US disclosed
US-7727992-B2 Gyrase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-01 US disclosed
US-20100105701-A1 GYRASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2010-04-29 US disclosed
EP-1511482-B1 2-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND/OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS VERTEX PHARMA (US) 2006-11-15 EP disclosed
EP-1511482-A1 2-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND/OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2005-03-09 EP disclosed
WO-2003105846-A1 2-UREIDO-6-HETEROARYL-3H-BENZOIMIDAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS GYRASE AND/OR TOPOISOMERASE IV INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105701-A1 GYRASE INHIBITORS AND USES THEREOF GMPS, NQO2, TOP1 NPSR1 4847/4885MEN1 4087/4885KMT2A 2852/4885
US-20110104207-A1 GYRASE INHIBITORS AND USES THEREOF GMPS, NQO2, TOP1 NPSR1 4847/4885MEN1 4087/4885KMT2A 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.